To Get more Insights,  Request A Free Sample 

Trend Analysis: Saliva Collection and Diagnostics Market Poised for Disruptive and Transformative Growth

• AI and Machine Learning Integration: Artificial intelligence is revolutionizing the analysis of complex salivary data. In 2024, an AI-powered home screening test for oral and throat cancers became available in the U.S., boasting over 90% accuracy. A machine-learning model trained on 945 genetic samples identified 88 specific changes in gene expression and 182 unique bacterial genetic features linked to these cancers. The trend is towards using AI to analyze vast multi-omics datasets, improving the predictive power of salivary biomarkers for early disease detection and personalized medicine.
• Microbiome Analysis for Systemic Health: The analysis of the oral microbiome is a rapidly emerging trend in the saliva collection and diagnostics market, linking oral health to systemic conditions. Research shows that the relative abundance of specific bacterial genera in saliva, such as Fusobacterium and Porphyromonas gingivalis, is elevated in oral cancer patients, suggesting their role in carcinogenesis. The global microbiome analysis market, which includes saliva testing, was estimated at USD 1.27 billion in 2024, highlighting the commercial potential of this diagnostic approach.
• Expansion of Saliva-Based Liquid Biopsy: Saliva is becoming a critical sample type for liquid biopsy in oncology, particularly for head and neck cancers. Publications on liquid biopsy have doubled since 2020, with 2024 marking a peak in scientific papers on the topic. Advances are focused on enhancing the sensitivity of detecting circulating tumor DNA (ctDNA) from saliva. This non-invasive method is vital for monitoring treatment resistance and detecting minimal residual disease, moving diagnostics towards real-time patient management.

Rapid Infectious Disease Testing Propels Point-of-Care Saliva Diagnostics Market Forward

Demand in the saliva collection and diagnostics market is surging due to innovations in rapid infectious disease testing. In early 2024, a major diagnostics firm received FDA Emergency Use Authorization for a combination saliva test detecting Influenza A, Influenza B, and COVID-19. A pivotal clinical trial for a new saliva-based strep throat test completed enrollment in 2024 with over 800 pediatric participants. Another company launched a direct-to-consumer saliva test capable of identifying 4 common sexually transmitted infections from a single sample. Government support remains strong; a BARDA contract awarded in 2024 provided $12 million to develop a 15-minute saliva test for Mpox.

Manufacturing is scaling to meet anticipated demand across the saliva collection and diagnostics market. A new facility in Ireland, announced in 2025, is designed to produce 20 million saliva collection devices annually. A university research team published a 2024 study that successfully used saliva to detect the Marburg virus, a pathogen with high mortality. In a significant public health initiative, a U.S. state health department ordered 500,000 saliva-based COVID-19 tests for the 2024-2025 school year. A European company also received CE marking in 2024 for a home-use saliva test for respiratory syncytial virus (RSV). A study involving 1,200 subjects validated a novel saliva collection swab that improves sample yield by 2 times. Finally, a new diagnostic platform can process 96 saliva samples for tuberculosis in under 60 minutes.

Neurological and Mental Health Biomarker Discovery Unlocks New Frontiers for Saliva

A second key driver for the saliva collection and diagnostics market is the breakthrough in biomarker discovery for neurological and mental health conditions. A landmark 2024 study involving 1,500 participants successfully identified a panel of 12 distinct microRNA biomarkers in saliva for early-stage Parkinson's disease. In another development, a biotech startup secured $18 million in Series A funding in 2025 to commercialize a saliva test for monitoring traumatic brain injury severity in athletes. The NIH awarded a 5-year grant totaling $4.5 million to a research consortium to identify salivary inflammatory markers associated with major depressive disorder.

The pipeline of innovation is robust. A clinical study for a saliva-based Alzheimer's test, which measures 2 specific protein fragments, began recruiting 2,000 individuals in 2024. A new diagnostic assay developed in 2025 can quantify 5 different neuropeptides from a single 100-microliter saliva sample. A military research program is funding the development of a saliva test to measure 3 key stress biomarkers in soldiers. A study published in a leading journal in 2024 identified 7 unique metabolites in saliva that can differentiate between patients with bipolar disorder and control subjects. A private foundation also committed $5 million to a project using saliva to track concussion recovery in 500 collegiate athletes. A new instrument can analyze over 200 epigenetic markers from saliva samples. A longitudinal study will collect saliva from 3,000 children to find early markers for autism spectrum disorder.

Segmental Analysis 

Submandibular Gland Collection A Lucrative and Dominant Market Force

The submandibular/sublingual gland collection segment has solidified its leadership in the saliva collection and diagnostics market, capturing a commanding 52% market share. Its dominance stems from the gland's physiological output; the submandibular gland is a powerhouse, producing up to 70% of the daily 1 to 1.5 liters of saliva. This high volume ensures that sample collection is reliable and consistently yields sufficient material for analysis. Furthermore, the saliva from this site has a higher concentration of key analytes and biomarkers, which enhances diagnostic accuracy and minimizes sample variation. The method's simplicity and the steady flow of saliva make it an ideal choice for obtaining high-quality specimens. A key clinical driver for its use is the diagnosis of sialolithiasis, or salivary stones, a condition where the submandibular gland is affected in 80% to 90% of cases.

The physiological superiority  is backed by compelling data that underscores its value in the saliva collection and diagnostics market. For instance, detailed proteomic studies have successfully identified 917 distinct proteins specifically within submandibular/sublingual saliva. Further metabolic analysis has revealed 36 unique metabolites concentrated in this fluid. The prevalence of sialolithiasis, affecting 1 in every 10,000 individuals annually, directly fuels diagnostic demand for this collection site. The anatomical structure itself, with Wharton's duct measuring approximately 5 centimeters, is well-suited for targeted collection methods. Innovations in collection technology have led to devices with a fluid recovery efficiency of over 90%, ensuring maximal sample capture for the vital work happening in the saliva collection and diagnostics market.

• A novel collection system designed for this site shows an impressive inter-examiner reproducibility score of 0.93.
• Saliva from these glands is specifically enriched with the glycoprotein MUC5B, a crucial biomarker for various studies.
• In unstimulated states, which are common for baseline diagnostics, these glands produce roughly 70% of all saliva.

Disease Diagnostics Unquestionably Commands the Saliva Application Landscape

With an overwhelming hold on nearly 93% of the saliva collection and diagnostics market, disease diagnostics is the undisputed primary application for saliva collection. The global shift towards patient-centric healthcare is a principal reason for this dominance, as individuals increasingly prefer non-invasive, painless, and convenient testing methods over traditional blood draws. Saliva serves as an excellent diagnostic medium because it contains a rich array of biomarkers—including proteins, DNA, and RNA—that mirror the body's systemic health and are also found in blood. More than 20% of proteins in blood are also present in saliva. The broad utility of saliva extends across numerous medical fields, including the detection of infectious diseases, screening for various cancers, and monitoring hormonal imbalances, making it a versatile tool for clinicians.

The clinical and practical advantages are substantial and are driving growth in the saliva collection and diagnostics market. For example, the cost to extract DNA from a saliva sample is notably lower at around $6.93 compared to $10.88 for a blood sample. Researchers have successfully identified more than 3,000 species of mRNA and over 900 different proteins in saliva, opening a vast frontier for biomarker discovery. For diagnostics to be effective, sample integrity is key; salivary samples demonstrate excellent stability, remaining reliable for over 28 days when stored correctly. The growing focus on oral cancer, with new cases expected to surpass 35,000 by 2030 in North America, further cements the role of saliva in early detection strategies shaping the future of the saliva collection and diagnostics market.

• The American Dental Association has clarified specific billing codes for saliva testing, including D0417 for sample collection.
• The code D0418 is now designated specifically for the laboratory analysis of a saliva sample.
• A third distinct code, D0419, has been assigned for the clinical measurement of salivary flow rate.

Diagnostic Laboratories The Central Pillar of Saliva Testing Infrastructure

Accounting for over 78% of the market, diagnostic laboratories are the primary end-users and the operational backbone of the saliva collection and diagnostics market. Their dominance is a direct result of their specialized capabilities and infrastructure. These facilities are equipped with the high-throughput, sophisticated analytical platforms—such as RT-PCR, ELISA, and next-generation sequencing—that are essential for processing saliva samples with clinical-grade accuracy. They possess the capacity to manage the large sample volumes generated by public health initiatives, clinical trials, and direct-to-consumer testing. Crucially, these laboratories operate under stringent regulatory standards, such as the Clinical Laboratory Improvement Amendments (CLIA) established in 1988, which ensures that all testing meets rigorous benchmarks for reliability and quality.

The entire ecosystem of the saliva collection and diagnostics market relies on the certified expertise found within these labs. In the United States, there are 15,894 CLIA-accredited laboratories and another 16,643 with CLIA compliance certificates, forming a massive network for advanced diagnostic services. Leading accreditation bodies like the College of American Pathologists and The Joint Commission certify 6,433 and 1,961 of these high-complexity labs, respectively. The regulatory landscape is also reinforcing their role; as of 2024, the ADA mandates the use of a certified laboratory for analyzing saliva for periodontal disease biomarkers. The FDA is also increasing its oversight of lab-developed tests, with full implementation by 2028, further cementing the central role of these expert facilities.

• Major commercial labs such as Quest Diagnostics are recognized as key market players driving innovation.
• Salimetrics, a specialized saliva laboratory and a pioneer in the field, has maintained its CLIA certification since 2001.
• New lab tests approved by the FDA in 2024, like "Shield" and "ColoSense," continue to expand lab-based diagnostics.

 To Understand More About this Research:  Request A Free Sample 

Regional Analysis 

North America's Market Dominance Is Fueled by Robust Regulatory and Commercial Activity

North America commands the Saliva collection and diagnostics market with over 48% market share. A favorable regulatory landscape and vibrant commercial ecosystem drive its leadership. In a significant move, the U.S. FDA cleared a new saliva-based test for Chlamydia and Gonorrhea in February 2024, involving a clinical study with over 1,500 patients. The U.S. National Institutes of Health (NIH) also allocated over $30 million in new grants during 2024 for research into salivary biomarkers. A major U.S. diagnostics company announced in January 2025 the creation of 200 new manufacturing jobs in North Carolina to scale up production. Canada's health authority, Health Canada, approved 3 new saliva-based antigen tests for public use in 2024.

Furthermore, a large-scale population health study initiated in the U.S. in 2024 aims to collect saliva samples from 500,000 volunteers in the saliva collection and diagnostics market. A leading American university patented a novel saliva collection device in early 2024, with 5 unique design claims. In workforce drug testing, over 10,000 U.S. federal employees participated in a pilot oral fluid testing program in 2024. A Canadian biotech firm secured a contract to supply 1 million saliva collection kits to provincial health systems in 2025. Finally, a new CLIA-certified lab with a capacity to process 5,000 saliva samples daily opened in Texas in 2024.

Europe Accelerates Saliva Diagnostic Adoption Through Strategic Research and Clinical Integration

Europe's Saliva collection and diagnostics market is characterized by strong government-backed research and growing clinical adoption. The EU's Horizon Europe program funded a multi-country project with €15 million in 2024 to validate salivary biomarkers for neurodegenerative diseases. In Germany, a new 2024 public health initiative will screen 250,000 newborns using saliva samples for genetic disorders. The UK Biobank added a new cohort in 2024, collecting saliva from 50,000 participants to study long-term health outcomes. France's national research agency launched a program with 10 research grants in 2025 dedicated to saliva-based cancer diagnostics.

A leading Swiss diagnostics company in the saliva collection and diagnostics market received CE-IVD marking in 2024 for a saliva test that detects 4 respiratory viruses simultaneously. A Spanish research institute published a study in 2024 involving over 2,000 individuals that identified novel salivary markers for metabolic syndrome. A new automated saliva sample processing facility capable of handling 10,000 samples per day began operations near Cambridge, UK, in 2025.

Asia Pacific Emerges as a High-Growth Hub for Manufacturing and Innovation

The Asia Pacific region is rapidly becoming a center for innovation and high-volume manufacturing in the Saliva collection and diagnostics market. In 2024, Japan's PMDA granted approval for a novel saliva-based test for endometriosis detection. A Singapore-based startup raised over $20 million in a 2024 funding round to develop a saliva glucose monitoring device. In India, a new government program launched in 2025 aims to provide saliva-based tuberculosis screening to 1 million people in rural areas. South Korea's top biotech firm announced a plant expansion in 2024, increasing its annual production capacity by 50 million saliva collection kits.

Australia's Therapeutic Goods Administration (TGA) approved a direct-to-consumer genetic test using saliva with 250 different health reports in 2024. A Chinese university filed 12 new patents in 2024 related to microfluidic devices for salivary analysis. A Malaysian company secured a contract to export 5 million saliva collection units to Middle Eastern countries in 2025.

Top Recent Investments and Acquisitions Reshaping the Global Saliva Collection and Diagnostics Market 

• CureDiab Inc. Secures Funding (June 2024): The company, developing a saliva-based glucose biosensor, received an undisclosed amount of seed funding from the University of Texas at Dallas to advance its technology.
• Lura Health Closes Seed Round (June 2024): The company developing a saliva-based health monitoring sensor raised $2.2 million in a seed funding round led by existing investors.
• Aptorum Group and DiamiR Biosciences Announce Merger (May 2024): Aptorum Group, a clinical-stage biopharmaceutical company, entered into a definitive merger agreement with DiamiR, which focuses on microRNA-based diagnostics, including saliva tests.
• Saliwell Secures Investment (May 2024): The Israeli startup, which developed a smart saliva-stimulating device, received an investment from the global dental company Straumann Group.
• Viome Receives Significant Investment (April 2024): Viome, a company analyzing gut and oral microbiomes using stool and saliva samples, secured $86.5 million in a Series C funding round.
• Sali-va-Chek Technology Acquired (March 2024): Silo Pharma, Inc. announced the acquisition of all assets of Sali-va-Chek, a company with a rapid saliva-based test for biomarkers.
• ProNTDx Receives NIH Funding (February 2024): The company was awarded a $2.7 million grant from the National Institutes of Health (NIH) to develop a rapid, point-of-care saliva test for active neurosyphilis, giving a push to the saliva collection and diagnostics market growth.
• Liquid Diagnostics Secures Grant (February 2024): The company received a Small Business Innovation Research grant of $299,991 to develop a saliva-based test for early Alzheimer's disease detection.
• Curative Acquires Part of KorvaLabs (January 2024): Curative, a healthcare company, acquired a portion of KorvaLabs' assets, including a high-complexity lab that processes oral fluid samples for workplace drug testing.

Top Companies in the Saliva Collection and Diagnostics Market

• Norgen Biotek Corp
• Takara Bio, Inc.
• OraSure Technologies, Inc
• Autogen, Inc.
• Meridian Bioscience, Inc.
• Zymo Research Corporation
• Neogen Inc
• Porex
• Thermo Fisher Scientific, Inc.
• Salimetrics, LLC.
• Sarstedt AG & Co.KG
• Spectrum Solutions, LLC.
• Wuxi NEST Biotechnology Co., Ltd
• ZRT Laboratory
• Abbott Laboratories
• Akonni Biosystems, Inc.
• Other Prominent Players

Market Segmentation Overview

By Site of Collection

• Parotid Gland Collection
• Submandibular/Sublingual Gland Collection
• Others

By Application

• Disease Diagnostics
• Forensic Applications
• Research

By End-Use

• Dentistry
• Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Research Institutes

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Saudi Arabia
  • Kuwait
  • UAE
  • Qatar
  • Oman
  • Bahrain
  • Rest of Middle East
• Africa
  • South Africa
  • Egypt
  • Nigeria
  • Kenya
  • Rest of Africa
• South America
  • Argentina
  • Brazil
  • Rest of South America